Orthopedic Surgery

New York City, NY, United States

Orthopedic Surgery

New York City, NY, United States
SEARCH FILTERS
Time filter
Source Type

(PRLEAP.COM) Louisville, KY. March 8, 2017. Louisville orthopedic surgeon and sports medicine physician Dr. Stacie L Grossfeld is welcoming Spanish speaking patients to her private medical practice Orthoapedic Specialists. In order to make this easier, Dr. Grossfeld recently hired staff member Ashley Milburn to join her team. Ms. Milburn, who is fluent in both English and Spanish, assists Spanish speaking patients with communicating with the doctor, understanding doctor's orders, translating paperwork and more.Ashley Milburn graduated from ATA College in Louisville, Kentucky. She completed the Limited Medical Radiography with Medical Assisting program (LMRMA) with an impressive 4.0 grade point average. During her time as a student, she did an externship at Dr. Grossfeld's medical practice, Orthopaedic Specialists. And when she finished her degree, Dr. Grossfeld invited her to join the team.Originally from Willisburg, Kentucky, Ms. Milburn grew up helping her family on a tobacco farm. During this time working with many Spanish-speaking farm employees, she became very interested in learning Spanish. Though she never received formal training, she is now a fluent Spanish speaker. She explains: "If you want to know what people are saying, you try hard to learn." Realizing the many benefits of speaking both English and Spanish, Ms. Milburn is also raising her three children to be bilingual.Along with her skills as a Medical Assistant and X-Ray Tech, Ashley's ability to speak Spanish has been a great skill for Orthopaedic Specialists. She enjoys helping Spanish-speaking clients. Describing her work, she explains: "I really enjoy helping people and it is great to help translate for someone who speaks Spanish. I love it when the Spanish-speaking patients tell me I speak Spanish well, and ask me what country I am from. They get really interested in how I learned it. It is a great feeling to be able to help people who might not be able to get the treatment they need."Along with working as a translator for Spanish-speaking patients, Milburn is currently working on translating all of the paperwork at Orthopaedic Specialists into Spanish including: surgery packets, pre-op and post-op instructions, sign in slips, new patient paperwork, and worker's compensation paperwork.Right now, Orthopaedic Specialist is accepting all new patients including those who are Spanish speakers . According to Milburn, most of the Spanish speaking patients they are currently serving at Orthopaedic Specialists are between the age of 30 and 60 years old. According to Louisville-area data, there are close to 30,000 Spanish-speaking people living in the Louisville Metro area with an average age of 27. Dr. Grossfeld is excited to be able to offer bilingual services to patients, and looks forward to providing orthopedic and sports medicine treatment to Spanish-speaking people in the Louisville, Kentucky area.Dr. Stacie L. Grossfeld is a double board-certified doctor in Orthopedic Surgery and Sports Medicine. After graduating from the University Of Louisville School Of Medicine, she went on to complete her internship and residency at the University of Minnesota. She also completed a Sports Medicine fellowship at the Fowler-Kennedy Sports Medicine Center.Along with her work at her private medical practice, Orthopaedic Specialists, Dr. Grossfeld also mentors medical students who are interested in the field of orthopedic surgery and sports medicine through the American Academy of Orthopedic Surgery. She also works as an Assistant Clinical Professor in the Department of Orthopedic Surgery at her alma mater – the University of Louisville School of Medicine.Outside of the medical field, Dr. Grossfeld spends time volunteering for various organizations in Louisville, KY. She is on the Board of Directors for both the YMCA at Norton Commons and the Louisville Sports Commission, where she also holds a chair position on the Louisville Active Committee. She also finds time to work with the American Medical Society for Sports Medicine as a mentor for prospective submissions. And she serves as an event doctor to numerous area sporting events including Derby City Cyclocross competitions.Dr. Grossfeld's dedication to making Louisville, KY, a better and healthier city for everyone expands across a wide variety of outlets which now includes offering professional orthopedic medical care to the city's Hispanic and Latino population. If you have been looking for an orthopedic medical office in Louisville, Kentucky, that serves the Spanish-speaking community, contact Orthoapedic Specialists today by calling 502-212-2663 or visiting them online


(PRLEAP.COM)Dr. Stacie Grossfeld, orthopedic surgeon at Orthopaedic Specialists, PLLC , has been named Volunteer of the Year by the YMCA at Norton Commons in Louisville, Kentucky. Since 2015, Dr. Stacie Grossfeld has served on the Board of Directors for the organization, and has regularly connected the YMCA with potential business partners since joining.Since joining the Norton Commons YMCA Board of Directors, Dr. Stacie Grossfeld has been happy to help fundraise for the Y at Norton Commons . Some examples of Dr. Grossfeld's involvement with the YMCA include:Describing their experience with Dr. Grossfeld, leaders at the YMCA at Norton Commons explain: "Stacie is a tremendous asset to the YMCA at Norton Commons and she is very deserving of our Volunteer of the Year Award!"The YMCA at Norton Commons is one of the newest YMCA facilities to open in the Greater Louisville area. At the Norton Commons YMCA, families can take advantage of a wide variety of programs including:The YMCA at Norton Commons also offers a warm water pool for recreational activities, a lap pool for exercise, a sauna, spa, group exercise and cycling classes, a fitness center, supervised Kid's Club, Club Y for preteens, a full gymnasium, and more.Dr. Stacie Grossfeld is known around Louisville for being an active member of the community. When she is not serving on the Board of Directors at the YMCA at Norton Commons, she can be found treating patients at her private orthopedic medical practice Orthopaedic Specialists. She also serves as an Assistant Clinical Professor in the Department of Orthopedic Surgery at the University of Louisville and she is on the Board of Directors for the Louisville Sports Commission Being named "Volunteer of the Year" by the YMCA at Norton Commons is a huge honor for Dr. Grossfeld. Over the years, Dr. Grossfeld has received many awards for her achievements and philanthropic work for the city of Louisville. She received the Small Business Owner of the Year Award in 2016 from the National Association of Women Business Owners (NAWBO), the Most Compassionate Doctor Award based on patient reviews, recognition as a Top Ten Orthopedic Doctor in Louisville, KY through American Top 10, and The Patients Choice Award through Vitals.com . However, the Volunteer of the Year award given to her by the YMCA at Norton Commons has a special place in her heart due to her extensive involvement in the YMCA community both personally and professionally.Dr. Stacie Grossfeld graduated from the University of Louisville School of Medicine and completed her internship and residency at the University of Minnesota. Dr. Grossfeld is double board-certified in sports medicine and orthopedic surgery. As an independent, non-hospital employed orthopedic surgeon, Dr. Grossfeld runs a private practice called Orthopaedic Specialists with several locations in Louisville. In addition to her work, Dr. Stacie Grossfeld is committed to serving her community as a mentor and philanthropist. In her spare time, when she is not working, volunteering, or serving on a local board, she enjoys playing sports including: tennis, cycling, and hiking. Outside of her career and sports, Dr. Grossfeld loves spending time with her family.Orthopaedic Specialists, PLLC has two convenient office locations in Louisville, KY . The office located in the St. Matthews area of Louisville is at 4001 Kresge Way in Louisville, Kentucky, 40207 on the third floor in Suite 303. The Jeffersontown location is located within the Baptist Health Urgent Care facility at 10261 Taylorsville Road, Louisville, Kentucky, 40299. Both offices offer treatment options for various orthopedic and sports medicine issues including: ankle and foot pain, knee injuries and reconstruction, shoulder injuries and reconstruction, sports medicine, ACL injuries, wrist, arm and elbow pain, hip injuries, and more. Dr. Grossfeld routinely performs arthroscopic rotator cuff repairs, ACL reconstructions, knee arthroscopy, labral repairs, and more, at her offices and in area-hospitals.If you are experiencing knee pain, shoulder pain, or have suffered from some type of sports injury, contact Dr. Stacie Grossfeld with Orthopaedic Specialists, PLLC today by calling 502-212-2663 or visiting Orthopaedic Specialists online


– Long history and significant US data package may enable full Marketing and Manufacturing Authorization of NeoCart subject to successful completion of small confirmatory clinical trial in Japan – – PMDA Consultations concluded in first quarter of 2017 encompass all parts of potential regulatory submission including:  Clinical Trial, Quality/Manufacturing and Non-Clinical Safety – – Japanese cartilage repair market estimated to be second largest in the world with established reimbursement, and physicians and patients seeking treatments for cartilage defects that may prevent osteoarthritis in the knee – WALTHAM, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that it has successfully completed all formal consultations with the Office of Cellular and Tissue-based Products of the Japan Pharmaceuticals and Medical Devices Agency (the PMDA) regarding the Marketing and Manufacturing Authorization pathway for Histogenics’ NeoCart (autologous cell therapy designed to treat cartilage defects in the knee) in the Japanese market.  Histogenics is currently nearing the completion of enrollment in a 245 patient Phase 3 clinical trial of NeoCart that is being conducted under a Special Protocol Assessment (the SPA) with the U.S. Food and Drug Administration (the FDA). “We are very pleased with the formal feedback we received from the PMDA regarding the relatively expeditious approval pathway for NeoCart in Japan, and appreciate the thoughtful, rapid and collaborative approach provided by Japan regulators,” stated Adam Gridley, President and Chief Executive Officer of Histogenics.  “These successful consultations and meetings are evidence of our execution of a broadening global regulatory strategy launched only seven months ago where we initiated efforts to leverage the robust U.S. clinical, preclinical and cGMP data for NeoCart into international markets.  We believe the clarity on this efficient regulatory pathway for full Marketing Authorization will be important to our efforts to seek a development and commercialization partner for NeoCart in Japan and other markets in Asia.” Various aspects of the Japanese regenerative medicine laws were updated in 2014 to potentially expedite the clinical development and commercialization pathways for innovative, qualified regenerative cell-based medicines that have demonstrated safety and probable efficacy.  Shortly after reacquiring Japanese rights for NeoCart from Purpose Co. in May 2016, Histogenics initiated preparatory pre-consultations (Jizen-Mendan) with the PMDA for the three discreet modules of the regulatory process: Clinical Trial, Non-clinical Safety and Quality/Manufacturing. During the first quarter of 2017, Histogenics held a series of consultations with the PMDA, including face-to-face (Taimen-Jogen) meetings.  In these consultations, the PMDA agreed that Histogenics’ ongoing Phase 3 clinical trial with its one-year primary endpoint could be appropriate and provide sufficient evidence of safety and effectiveness for the full Marketing and Manufacturing Authorization in Japan. Furthermore, the PMDA agreed that a 30-patient, one-year confirmatory clinical trial in Japanese patients, comparing NeoCart to microfracture, would be sufficient for applying for full Marketing and Manufacturing Authorization in Japan.  This Japanese study will utilize the same protocol as the ongoing Phase 3 clinical trial of NeoCart.  Histogenics also confirmed that NeoCart would be regulated as a Regenerative Medical Product, as covered by the recently enacted laws in Japan, and that Histogenics’ current good manufacturing process (cGMP) in the U.S. could be utilized to manufacture and supply the confirmatory clinical study. These consultations with the PMDA were attended by representatives of Histogenics, including co-founder Dr. Shuichi Mizuno, regulatory and regenerative medicine experts, and two esteemed orthopedic surgeons from Japan, Dr. Akihiro Tsuchiya and Dr. Takumi Nakagawa, both of whom have trained on NeoCart procedures with U.S. surgeons. In addition to the confirmatory clinical trial, Histogenics agreed with the PMDA to conduct additional minor, non-clinical safety studies, including a short-term (three-month) general toxicity study and in vitro tumorigenicity studies to reflect current standards and to augment the significant amount of pre-clinical data previously generated by Histogenics.  These additional study protocols will be reviewed with the PMDA and will be conducted prior to the Marketing and Manufacturing Authorization.  With regards to Histogenics’ Quality/Manufacturing applications, the PMDA and Histogenics agreed to several updates for certain procedures and testing methodology, all of which are planned as part of Histogenics’ continuous improvement activities for the biologics license application (BLA) submission planned with the FDA. Histogenics believes that the PMDA’s conclusions are based on the strength of the NeoCart clinical and non-clinical data package and the long 15+ year cGMP manufacturing history of NeoCart. “We are thankful for the leadership and partnership with the PMDA,” commented Dr. Shuichi Mizuno, Ph.D., Co-founder of Histogenics, and Assistant Professor, Orthopedic Surgery, Brigham and Women’s Hospital, and Harvard Medical School.  “We have been working collaboratively for nearly 20 years to provide substantial supportive basic science and non-clinical data as well as novel cell culture technology to guide the development of this important innovative therapy for cartilage defects.” In conjunction with the launch of its commercial partnering efforts, Histogenics commissioned through Locust Walk’s Japan team a quantitative market research study with approximately 80 orthopedic surgeons including a mix of hospital physicians and general practitioners in Japan regarding the market opportunity for NeoCart for knee cartilage defects in the Japanese market.  The findings paralleled what is observed from surgeons and patients in the United States – a market with a high unmet need characterized by long recoveries and variable clinical outcomes from current therapies, leaving many patients choosing to avoid having unsatisfactory treatments.  These data may reflect the opportunity for innovative regenerative medicine products such as NeoCart to grow the market substantially by providing satisfactory outcomes and better quality of life, while avoiding progression to osteoarthritis (OA) and unnecessary surgeries. The findings from the Japan survey include: “As is the case in the United States, we believe Japanese surgeons and patients are seeking new regenerative medicine options to repair cartilage defects that may offer both a more rapid recovery in terms of pain and function, as well as a more durable response over time with fewer repeat surgeries, which improves overall quality of life,” commented Dr. Tsuchiya, Vice President, Funabashi Orthopaedic Hospital, Chiba, Japan, and Chairman, Tokyo Women’s Medical College, Tokyo, Japan, and Dr. Nakagawa, Professor of Department of Orthopaedic Surgery, School of Medicine, Teikyo University, Tokyo, Japan.  “We have followed the development of NeoCart for many years and have trained with surgeons in the U.S., and along with our medical colleagues, look forward to potentially introducing this novel non-NSAID and non-opioid cell-based therapy product to our patients in Japan that currently do not have good options to treat the pain and loss of function due to knee cartilage defects.” Histogenics estimates the Japanese market represents a significant opportunity, with an estimated 200,000 procedures annually in Japan for patients suffering from pain associated with cartilage defects in the knee and limited options to treat the defect or related pain.  If left untreated, cartilage defects may result in OA and ultimately, total knee replacements as patients age, with a substantial economic impact on patients and insurance companies.  Market forecasts predict that the number of OA patients in Japan aged 40 and older amounts to more than 25 million and is expected to accelerate with the aging population. Once a development and commercial partner is identified, Histogenics intends to file with such partner the Clinical Trial Notification (CTN) to the PMDA to begin the proposed clinical trial. About Histogenics Corporation Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace.  Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions.  Histogenics’ first investigational product candidate, NeoCart is currently in Phase 3 clinical development.  NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options.  For more information, please visit www.histogenics.com. Various statements in this release are “forward-looking statements” under the securities laws. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements.  Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Histogenics’ forward-looking statements include, among others:  the timing and success of Histogenics’ NeoCart Phase 3 clinical trial; possible delays in enrolling the NeoCart Phase 3 clinical trial; the ability to obtain and maintain regulatory approval of NeoCart or any product candidates in the U.S. and Japan, and the labeling for any approved products; Histogenics’ ability to find a development and commercialization partner for NeoCart in Japan; the scope, progress, expansion, and costs of developing and commercializing Histogenics’ product candidates; the ability to obtain and maintain regulatory approval regarding the comparability of critical NeoCart raw materials; the size and growth of the potential markets for Histogenics’ product candidates and the ability to serve those markets; Histogenics’ expectations regarding its expenses and revenue; the sufficiency of Histogenics’ cash resources and the availability of additional financing on commercially reasonable terms; the early stage of development of the technologies on which Histogenics’ channel partnering agreement with Intrexon is based; the additional expenses that Histogenics may incur in connection with its exclusive channel collaboration agreement with Intrexon Corporation and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Histogenics’ Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC and available on the SEC’s website at www.sec.gov.  Additional factors may be set forth in those sections of Histogenics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, to be filed with the SEC in the second quarter of 2017.  In addition to the risks described above and in Histogenics’ annual report on Form 10-K and quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Histogenics’ results. There can be no assurance that the actual results or developments anticipated by Histogenics will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Histogenics.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | March 17, 2017
Site: www.techtimes.com

Spinal deformity is caused due to unnatural curvature and it takes place mostly due to any defect, or damage caused to the spine. Patients who are suffering from spinal deformity are at greater risk of dislocation following a hip replacement surgery if a new study is to be believed. The study was conducted by orthopedic surgeons of the NYU Langone Medical Center. The research includes a detailed observation of the affects of spinal deformity on the pelvis. It states the risks which are involved in such cases, while surgeons try to attach the artificial hip during a replacement surgery. During a hip replacement surgery, the surgeon attaches an artificial joint which includes a socket and a ball to the natural sockets located in the pelvis of the patient. Surgeons have tried to attach the socket or the acetabular cup adjoining the pelvic bone, which according to them is a safe zone or is a place where there are less chances of dislocation. This process has been used by surgeons for years. However, a new study suggests that attaching the artificial cup at the safe area is not sufficient to avoid dislocations in patients suffering from deformity. During the research, the investigators studied 107 patients who had been affected with sagittal spinal deformity. They also reviewed 139 patients who had undergone a hip replacement surgery. The detailed report of the measurements of the patients taken before and after the surgery were analyzed. The researchers studied the dynamic changes which took place in the acetabular cup position, and also inquired the instability rate in the patients who underwent hip replacement surgery. The investigators found that the dislocation rate is 8 percent for patients who are suffering from some kind of spinal stenosis. About 5.8 percent patients required another operation because of the reoccurrence of the dislocation. "The fact that high rates of dislocation occurred in patients with 'safe zone' placement of their artificial hips implies that our understanding of what defines acceptable acetabular positioning for these patients remains questionable," said Jonathan Vigdorchik, Assistant Professor of Orthopedic Surgery in NYU Langone. These findings have led orthopedic surgeons at NYU Langone to work together with other spine surgeons. They intend to work on planning preoperative measures, which should be taken to achieve the best possible results for hip replacement surgeries. The researchers are also planning to examine ways through which further dislocation risks, that are involved in hip replacement surgeries, can be reduced. This research was presented at the at the American Academy of Orthopedic Surgeons (AAOS) 2017 Annual Meeting in San Diego, California on March 17. The study is available online in the Journal of Arthroplasty. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.


With profits margins rapidly shrinking and the threat of alternatives becoming a huge challenge, companies operational in the field are focusing on expansion across emerging economies where the high prevalence of cardiovascular diseases is leading to a huge surge in open-heart surgeries. An instance of this would be Medtronic's acquisition of Covidien plc., an Ireland-based healthcare company and manufacturer of medical devices and supplies, in 2015. The acquisition helped the former gain benefits such as expanding geographical access to a high-growth potential region and lower operational costs. Transparency Market Research states that the global market for Surgical Sutures will exhibit a 3.9% CAGR from 2017 to 2025, rising to a valuation of US$5,080.1 mn by 2025. North America to Retain Leadership Position in Terms of Revenue Contribution On the basis of product type, the segment of absorbable sutures, which accounted for a nearly 60% of the overall market in terms of revenue contribution in 2016, is expected to remain the leading segment throughout the forecast period. The segment is expected to offer an incremental opportunity of nearly US$880 mn between 2017 and 2025. Geographically, the North America market dominated the global market in 2015, accounting for a nearly 35%. Factors such as the rising numbers of orthopedic surgeries and the high per capita expenditure on healthcare will continue to drive the strong demand for surgical sutures in the North America market throughout the forecast period. The rising global demand for surgical sutures is chiefly attributed to increasing numbers of surgical procedures, surging global population, rapidly expanding geriatric population base across developed and developing economies, rising disposable incomes, and the rising willingness of the global population to spend on healthcare and wellness. Technological advancements enabling the development of suture materials capable of improving wound closure time and tissue approximation, which add more value to the final result of surgeries, are also fueling the uptake of surgical sutures across the globe. Moreover, the vast improvements observed in healthcare facilities such as the rising numbers of clinics and hospitals, especially in developing economies, are also intensifying the growth opportunities of the global surgical sutures market. However, certain factors, such as the availability of other advanced wound closure materials and the burgeoning demand for minimally invasive procedures could hamper the growth prospects of the global surgical sutures market to some extent during the forecast period. The rising demand for precision surgical sutures and the rising number of vendors, especially in several developing economies where a number of local manufacturers offer surgical sutures at significantly low prices, have intensified price wars. The need to offer products at low costs to survive in such environment is adversely affecting the profit margins of leading players, which is consecutively bringing down funds usually invested in R&D activities and eventually resulting in the lack of innovative products in the global market. This analysis of the global surgical sutures market is based on a recent market research report published by Transparency Market Research, titled "Surgical Sutures Market (Product Type - Absorbable Sutures (Natural Sutures and Synthetic Sutures) and Non-absorbable Sutures (Nylon Sutures, Polypropylene Sutures, and Stainless Steel Sutures); Application - General Surgery, Gynecological Surgeries, Cardiovascular Surgeries, Orthopedic Surgeries, Other Surgeries; End-users - Hospitals, Specialty Clinics, and Ambulatory Surgery Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024." For the study, the market has been segmented as follows: Endoscopy Devices Market (Device Type - Endoscopes (Rigid Endoscope, Flexible Endoscope, Capsule Endoscope, and Robot Assisted Endoscope), Operative Devices (Energy Systems, Access Devices, Suction/Irrigation Systems, Operative Hand Instruments, Insufflation Devices, Wound Protectors, and Snares), and Visualization Systems (Standard Definition (SD) Visualization Systems, High Definition (HD) Visualization Systems, and Ultrasound Devices); Application - Gastrointestinal Surgeries, Urology/Gynecology Surgeries, ENT Surgeries, Cardiovascular Surgeries, Neuro/Spinal Surgeries, Laparoscopy Surgeries, and Arthroscopy Surgeries) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Image Guided Surgery Devices Market (By Types: CT, Ultrasound, MRI, Endoscopes, X-Ray Fluoroscopy, PET, and SPECT; By Application: Neurology, Orthopedic Surgery, ENT, Oncology Surgery, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


Stanley G. Tangalakis is pleased to announce the appointment of his son-in law, John M. Gargaro, MD as President and CEO effective August 1, 2017.  Mr. Tangalakis will remain active in the business as owner and Chairman of the Board. Dr. Gargaro, a board certified orthopedic surgeon, graduated from Harvard University and the University of Michigan Medical School. He currently serves as Chief of the Department of Orthopedic Surgery at Kaiser Permanente, Colorado. “We are pleased to have Dr. Gargaro join Mercury Medical, bringing with him his innovative leadership style and extensive medical knowledge,” said Stanley G. Tangalakis, owner and Chairman of the Board of Mercury Medical. Dr. Gargaro has held several leadership positions in the past, including Chairman of the Department of Orthopedic Surgery and Secretary-Treasurer of the medical staff at St. Joseph Hospital in Denver, Colorado. Dr. Gargaro has consulted with Wright Medical and Johnson & Johnson/DePuy, as well as held clinical research and speaker panel positions for Sanofi-Synthelabo and Organon Labs in the pharmaceutical field. For over 50 years, Mercury Medical, a veteran-owned medical products company headquartered in Clearwater, Florida, has been recognized by the industry as a leading provider of innovative airway management devices. For more information, visit www.mercurymed.com or contact Deborah Olson, Director of Marketing at dolson@mercurymed.com.


With profits margins rapidly shrinking and the threat of alternatives becoming a huge challenge, companies operational in the field are focusing on expansion across emerging economies where the high prevalence of cardiovascular diseases is leading to a huge surge in open-heart surgeries. An instance of this would be Medtronic's acquisition of Covidien plc., an Ireland-based healthcare company and manufacturer of medical devices and supplies, in 2015. The acquisition helped the former gain benefits such as expanding geographical access to a high-growth potential region and lower operational costs. Transparency Market Research states that the global market for Surgical Sutures will exhibit a 3.9% CAGR from 2017 to 2025, rising to a valuation of US$5,080.1 mn by 2025. North America to Retain Leadership Position in Terms of Revenue Contribution On the basis of product type, the segment of absorbable sutures, which accounted for a nearly 60% of the overall market in terms of revenue contribution in 2016, is expected to remain the leading segment throughout the forecast period. The segment is expected to offer an incremental opportunity of nearly US$880 mn between 2017 and 2025. Geographically, the North America market dominated the global market in 2015, accounting for a nearly 35%. Factors such as the rising numbers of orthopedic surgeries and the high per capita expenditure on healthcare will continue to drive the strong demand for surgical sutures in the North America market throughout the forecast period. The rising global demand for surgical sutures is chiefly attributed to increasing numbers of surgical procedures, surging global population, rapidly expanding geriatric population base across developed and developing economies, rising disposable incomes, and the rising willingness of the global population to spend on healthcare and wellness. Technological advancements enabling the development of suture materials capable of improving wound closure time and tissue approximation, which add more value to the final result of surgeries, are also fueling the uptake of surgical sutures across the globe. Moreover, the vast improvements observed in healthcare facilities such as the rising numbers of clinics and hospitals, especially in developing economies, are also intensifying the growth opportunities of the global surgical sutures market. However, certain factors, such as the availability of other advanced wound closure materials and the burgeoning demand for minimally invasive procedures could hamper the growth prospects of the global surgical sutures market to some extent during the forecast period. The rising demand for precision surgical sutures and the rising number of vendors, especially in several developing economies where a number of local manufacturers offer surgical sutures at significantly low prices, have intensified price wars. The need to offer products at low costs to survive in such environment is adversely affecting the profit margins of leading players, which is consecutively bringing down funds usually invested in R&D activities and eventually resulting in the lack of innovative products in the global market. This analysis of the global surgical sutures market is based on a recent market research report published by Transparency Market Research, titled "Surgical Sutures Market (Product Type - Absorbable Sutures (Natural Sutures and Synthetic Sutures) and Non-absorbable Sutures (Nylon Sutures, Polypropylene Sutures, and Stainless Steel Sutures); Application - General Surgery, Gynecological Surgeries, Cardiovascular Surgeries, Orthopedic Surgeries, Other Surgeries; End-users - Hospitals, Specialty Clinics, and Ambulatory Surgery Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024." For the study, the market has been segmented as follows: Endoscopy Devices Market (Device Type - Endoscopes (Rigid Endoscope, Flexible Endoscope, Capsule Endoscope, and Robot Assisted Endoscope), Operative Devices (Energy Systems, Access Devices, Suction/Irrigation Systems, Operative Hand Instruments, Insufflation Devices, Wound Protectors, and Snares), and Visualization Systems (Standard Definition (SD) Visualization Systems, High Definition (HD) Visualization Systems, and Ultrasound Devices); Application - Gastrointestinal Surgeries, Urology/Gynecology Surgeries, ENT Surgeries, Cardiovascular Surgeries, Neuro/Spinal Surgeries, Laparoscopy Surgeries, and Arthroscopy Surgeries) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Image Guided Surgery Devices Market (By Types: CT, Ultrasound, MRI, Endoscopes, X-Ray Fluoroscopy, PET, and SPECT; By Application: Neurology, Orthopedic Surgery, ENT, Oncology Surgery, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


Frank X. Pedlow, MD, Orthopedic Surgeon currently serving patients within his own private practice, and affiliated with Massachusetts General Hospital and St. Elizabeth’s Medical Center, has been named a 2017 Top Doctor in Boston, Massachusetts. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Frank X. Pedlow is a very experienced orthopedic surgeon, and is one of the only spine surgeons in New England that has received training in both the Neurosurgical and Orthopaedic principles and techniques of spine surgery. His successful career in medicine began in 1986, when he graduated from New York Medical College. Upon receiving his Medical Degree, he completed his residency in Orthopaedic Surgery in the Harvard Combined Orthopaedic Residency Program, and served as Chief Resident at Massachusetts General Hospital. He then undertook his Spinal Surgery fellowship at Emory University Spine Center. Dr. Pedlow previously served as a Neurosurgery Fellow at LIJ Medical Center, and also spent time training internationally in Orthopedic Surgery at the University of Montreal in Canada, the Royal National Orthopedic Hospital in England, and the Robert Jones and Agnes Hunt Orthopedic Hospital in England. Dr. Pedlow is board certified by the American Board of Orthopaedic Surgery, and provides surgical and non-surgical solutions for a wide range of conditions and injuries. His practice specializes in the diagnosis and treatment of degenerative conditions of the neck and back, minimally invasive spine surgery, motion preservation surgery including cervical artificial disc replacement, athletic injuries to the spine, and spine care of the injured worker. He is particularly renowned as a specialist in the treatment of complex spinal disorders. For his excellence, Dr. Pedlow has been named a top doctor in Boston Magazine’s “Best Doctors” issue, and consistently has been named by Best Doctors, Inc. as one of the best orthopaedic spine surgeons in Boston, receiving this honor more than any other orthopaedic spine surgeon in Boston. Dr. Pedlow has also been named one of the region’s “Top Doctors” by Castle Connolly Medical, Ltd, has served as the spine consultant for the Boston Bruins, and has treated players from every major professional and many collegiate sports team in Boston. His dedication to his work and extensive expertise in his specialty makes Dr. Frank X. Pedlow a very worthy winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.


(PRLEAP.COM) Louisville, KY - May 12, 2017 - Dr. Stacie Grossfeld - one of Louisville, KY's Top 10 Orthopedic Physicians - is now offering subchondroplasty procedures to help ease pain for patients suffering from osteoarthritis, bone marrow edema, or insufficiency fractures in their knees. Dr. Grossfeld has been successfully practicing this minimally invasive procedure for the past year at Orthopaedic Specialists PLLC in Louisville, KY, and she wants to raise awareness of the benefits subchondroplasty offers to patients suffering from knee bone and joint degeneration.In the past, studies have shown that patients with osteoarthritis, bone marrow edema, or insufficiency fractures in their knees suffer from accelerated joint degeneration . If these health issues are targeted and treated with subchondroplasty, pain in the affected areas can be reduced and joint degeneration can be slowed down.Dr. Grossfeld is always trying to find innovative ways to reduce the number of patients that come into her office to undergo knee joint replacement surgery. An interesting research study authored by Scher et. al. in 2008 revealed that patients who showed signs of osteoarthritis, bone marrow edema, or insufficiency fractures on their MRI scans were nine times more likely to need another replacement over a three year time period. Through subchondroplasty, Dr. Grossfeld is able to safely delay knee joint replacement surgery until patients are older and less active.Subchondroplasty is a minimally-invasive, outpatient surgical procedure that is done in an operating room. Since bone marrow lesions cannot be detected or diagnosed using x-rays, MRI scans are used to map and locate the lesions. Using the preoperative MRI scan as a mapping device, the knee joint is scoped arthroscopically during the surgery.Once the lesions are located, Dr. Grossfeld performs arthroscopic debridement to remove damaged cartilage and bone from the affected area before using a trocar needle to inject liquid synthetic calcium phosphate bone filler where the bone marrow lesion is located.Removing the damaged cartilage and bone prior to injecting the liquid synthetic calcium phosphate bone filler is part of the surgical process due to a two year study performed by Drs. Steven Cohen and Peter Sharkley from the Department of Orthopedic Surgery at Thomas Jefferson University in Philadelphia, PA. These researchers found that patients who underwent subchondroplasty after arthroscopic debridement experienced significant reductions in pain for up to two years postoperatively compared to patients who did not undergo the same procedures.By injecting the affected area with synthetic calcium phosphate bone filler, the bone marrow lesion in the area of the compromised bone "heals". It takes 8 minutes for the bone filler to set and harden. Once the filler is hardened, the arthroscopy is completed. Following surgery, patients are able to bear weight on the knee joints and resume activity.The critical benefit of the subchondroplasty procedure is that patients who receive the injections are not compromised if they are to ever need knee joint replacement surgery . Subchondroplasty is proven to delay knee joint degeneration, ease osteoarthritis pain, and heal bone marrow lesions. Dr. Grossfeld offers subchondroplasty to patients who are looking to ease knee joint pain without undergoing major surgery or affecting their active lifestyles.Orthopedic surgeon Dr. Stacie Grossfeld first became interested in orthopedics thanks to her love of competitive sports. While she was growing up in northern Wisconsin, Dr. Grossfeld was an active cross country ski racer and a competitive cyclist. Throughout high school, she ran cross country, as well as track, and her love for fitness and sports that first got her interested in orthopedics is still strong today.After graduating from the University of Louisville School of Medicine, Dr. Grossfeld completed her internship and residency at the University of Minnesota before accepting a fellowship in sports medicine at the Fowler-Kennedy Sports Medicine Center in London, Ontario, Canada. Now, she is double-board certified in orthopedic surgery and sports medicine through the American Board of Orthopedic Surgeons and runs a private practice, Orthopaedic Specialists PLLC, in Louisville, KY.Outside of work, Dr. Grossfeld is an active philanthropist and mentor in her community. She spends time working at her alma mater as an Assistant Clinical Professor in the Department of Orthopedic Surgery, participates in the University of Louisville's Guaranteed Entrance to Medical School (GEMS) program by offering students the opportunity to learn more about orthopedic surgery, and serves on the board of various area organizations including the YMCA and the Louisville Sports Commission . She also enjoys playing tennis, cycling, weightlifting, and spending time with her family.Orthopaedic Specialists PLLC offers two convenient locations in Louisville, KY . Patients receive treatment options for a wide range of sports injuries and orthopedic conditions including: knee injuries and reconstruction, shoulder injuries and reconstruction, sports medicine, foot and ankle injuries, elbow injuries, hip pain, ACL injuries, and much more. Additionally, Dr. Grossfeld routinely performs arthroscopic rotator cuff repairs, ACL reconstructions, platelet rich plasma (PRP) injections and subchondroplasty procedures.If you or someone you love is experiencing knee joint pain and is interested in learning more about alternative options to help reduce pain and regain mobility, contact Dr. Stacie Grossfeld at Orthopaedic Specialists PLLC today. Call 502-212-2663 or visit Orthopaedic Specialists online to learn more about Dr. Stacie Grossfeld and how she can help.

Loading Orthopedic Surgery collaborators
Loading Orthopedic Surgery collaborators